drugset
drugset / Trial / NCT01417052

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

NCT01417052 ↗

Phase 1 Completed 10 enrolled Lexicon Pharmaceuticals
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to determine the safety of LX3305 in a dose escalation compared with placebo over 12 weeks in subjects with active rheumatoid arthritis (RA).

Timeline

Start
2011-09
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject LX3305 Small molecule 50 mg Oral
Subject LX3305 Small molecule 100 mg Oral
Subject LX3305 Small molecule 150 mg Oral
Subject LX3305 Small molecule 200 mg Oral
Subject LX3305 Small molecule 250 mg Oral
Subject LX3305 Small molecule 300 mg Oral
Subject LX3305 Small molecule 400 mg Oral
Subject LX3305 Small molecule 500 mg Oral

Indications

rheumatoid arthritis